Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.34 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.34 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6536106 | 1.00 | SLC7A5 (0.36) | SLC7A5CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL2027762 | 1.00 | SLC7A5 (0.36) | SLC7A5CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL866414 | 1.00 | SLC7A5 (0.36) | SLC7A5CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL17222464 | 1.00 | SLC7A5 (0.36) | SLC7A5CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL4256725 | 0.91 | TSHR (0.33) | SLC7A5CHRNB2CHRNB4CHRNA3CHRNA4 | |
| Ethylene Glycol SCHEMBL15602746 | 0.89 | CHRNB2 (0.34) | SLC7A5CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL29397848 | 0.89 | TP53 (0.36) | SLC7A5CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL12273577 | 0.89 | TP53 (0.36) | SLC7A5CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL11452947 | 0.87 | GRIN2D (0.30) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL10710883 | 0.87 | SLC7A5 (0.46) | SLC7A5GRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023200842-A1 | COMPOSITIONS AND METHODS FOR TREATING SOLID CANCER | EXOXEMIS, INC. (US) | 2023-10-19 | — | — | WO | claimed |
| EP-3463431-A1 | MYELOPEROXIDASE COMPOSITIONS AND METHODS FOR INHIBITION OF LIPOPOLYSACCHARIDES AND LIPID A | Exoxemis, Inc. (US) | 2019-04-10 | — | — | EP | claimed |
| CN-109414485-A | For inhibiting the myeloperoxidase enzymatic compositions and method of lipopolysaccharides and lipid A | 埃欧艾米斯公司 | 2019-03-01 | — | — | CN | claimed |
| CN-106432676-B | A kind of preparation method of N/P/ nanometers of synergistic extinguishing waterborn polyurethane dispersion liquid | 齐鲁工业大学 | 2018-12-25 | — | — | CN | claimed |
| WO-2017204918-A1 | MYELOPEROXIDASE COMPOSITIONS AND METHODS FOR INHIBITION OF LIPOPOLYSACCHARIDES AND LIPID A | EXOXEMIS, INC. (US) | 2017-11-30 | — | — | WO | claimed |
| CN-106432676-A | Preparation method of N/P/nano synergistic flame-retardant waterborne polyurethane dispersion liquid | 齐鲁工业大学 | 2017-02-22 | — | — | CN | claimed |
| EP-2731601-A2 | EOSINOPHIL PEROXIDASE COMPOSITIONS AND METHODS OF THEIR USE | Exoxemis, Inc. (US) | 2014-05-21 | — | — | EP | claimed |
| WO-2013009910-A2 | EOSINOPHIL PEROXIDASE COMPOSITIONS AND METHODS OF THEIR USE | EXOXEMIS, INC. (US) | 2013-01-17 | — | — | WO | claimed |
| CN-102014950-A | Compositions for enhancing the antibacterial activity of myeloperoxidase and methods of use thereof | EXOXEMIS INC | 2011-04-13 | — | — | CN | claimed |
| EP-2296693-A1 | COMPOSITIONS FOR ENHANCING THE ANTIBACTERIAL ACTIVITY OF MYELOPEROXIDASE AND METHODS OF USE THEREOF | Exoxemis, Inc. (US) | 2011-03-23 | — | — | EP | claimed |
| WO-2009137697-A1 | COMPOSITIONS FOR ENHANCING THE ANTIBACTERIAL ACTIVITY OF MYELOPEROXIDASE AND METHODS OF USE THEREOF | EXOXEMIS, INC. (US) | 2009-11-12 | — | — | WO | claimed |
| CN-1325063-C | L-amino acid water-soluble pearl powder and its preparing method | SONG TINGSHENG (CN) | 2007-07-11 | — | — | CN | claimed |
| CN-1709282-A | L-amino acid water-soluble pearl powder and its preparing method | SONG TINGSHENG (CN) | 2005-12-21 | — | — | CN | claimed |
| EP-0199432-B1 | ASSAYING METHOD FOR PRIMARY AMINES USING AROMATIC DIALDEHYDES | OREAD LABORATORIES, INC. (US) | 1991-05-29 | — | — | EP | claimed |
| JP-58116683-A | — | — | None | — | — | JP | disclosed |
| US-12636312-B2 | Gold clusters (AuCs), composition and method for treatment of liver cirrhosis | WUHAN VAST CONDUCT SCIENCE FOUNDATION CO., LTD. (CN) | 2026-05-26 | — | — | US | disclosed |
| US-20250325635-A1 | MODIFIED VASOACTIVE INTESTINAL PEPTIDES | IMMUNOFORGE CO LTD (KR) | 2025-10-23 | — | — | US | disclosed |
| US-4382081-A | ANTIARRTHRITIC AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1983-05-03 | — | — | US | disclosed |
| US-4312885-A | ANORECTIC AGENTS FOR TREATMENT OF OBESITY | HOFFMANN-LA ROCHE INC. (US) | 1982-01-26 | — | — | US | disclosed |
| US-4084980-A | STABILIZERS OF ACTIVATED CARBON, ZEOLITE, SILICA GEL, CARBON BLACK, TALC, AND MICA | SHIKOKU KAKEN KOGYO KABUSHIKI KAISHA (JA) | 1978-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12636312-B2 | Gold clusters (AuCs), composition and method for treatment of liver cirrhosis | FABP1, ALB, CSTB | SLC7A5 104/4885CHRNB2 2380/4885CHRNB4 2880/4885 |
| US-20250325635-A1 | MODIFIED VASOACTIVE INTESTINAL PEPTIDES | VIP, VIPR1, VIPR2 | SLC7A5 776/4885CHRNB2 314/4885CHRNB4 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.